Every guy who takes Viagra has probably read the warnings, which I've pasted below. Have these warnings cut down on the use of blue pills? I doubt it. All other things being equal, I do think that those risks are outweighed by the benefits of being able to play, play longer, and get off more.
However, your points regarding the differences between men and women are, as always, right-on and well-taken. For the record, I would like to apply for the job title "G-Spotter". (And my manicure is impeccable.) I'll bring the bottle of good lube if you'll bring the toys, and you can show me your definition of "extended play and experimentation."
VIAGRA SIDE-EFFECTS:
Headache
Flushing
Dyspepsia
Nasal Congestion
Urinary Tract Infection
Abnormal Vision
Diarrhea
Dizziness
Rash
Body as a whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury.
Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation,
hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest,
heart failure, abnormal electrocardiogram, cardiomyopathy.
Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis.
Hemic and Lymphatic: anemia and leukopenia.
Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral
edema, hyperuricemia, hypoglycemic reaction, hypernatremia.
Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain,
myasthenia, synovitis.
Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia.
Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased.
Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact
dermatitis, exfoliative dermatitis.
Special Senses: mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, deafness, ear pain, eye hemorrhage, cataract, dry eyes.
Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence,
abnormal ejaculation, genital edema and anorgasmia.
POST-MARKETING EXPERIENCE:
Cardiovascular and cerebrovascular
Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction,
sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic
attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of VIAGRA. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of VIAGRA without sexual activity. Others were reported to have occurred hours to days after the use of VIAGRA and sexual activity. It is not possible to determine whether these events are related directly to VIAGRA, to sexual activity, to the patient’s underlying
cardiovascular disease, to a combination of these factors, or to other factors (see WARNINGS
for further important cardiovascular information).
Other events reported post-marketing to have been observed in temporal association with VIAGRA and not listed in the pre-marketing adverse reactions section above include:
Nervous: seizure and anxiety.
Urogenital: prolonged erection, priapism (see WARNINGS), and hematuria.
Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot
appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous detachment/traction, paramacular edema and epistaxis.
Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including
permanent loss of vision, has been reported rarely post-marketing in temporal association with
the use of phosphodiesterase type 5 (PDE5) inhibitors, including VIAGRA. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to
determine whether these events are related directly to the use of PDE5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors.
